133031-38-6

Basic information

• Product Name: (2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one
• Synonyms: (2E)-1-(4-Chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one; 2-propen-1-one, 1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)-, (2E)-
• CAS NO: 133031-38-6
• Molecular Formula: C₁₅H₉Cl₃O
• Molecular Weight: 311.5904
• Mol File: 133031-38-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 448.5°C at 760 mmHg
• Flash Point: 189°C
• Density: 1.38g/cm³
• Vapor Pressure: 3.08E-08mmHg at 25°C
• Refractive Index: 1.644
• CAS DataBase Reference: (2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one(133031-38-6)
• EPA Substance Registry System: (2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one(133031-38-6)

Safety Data

• Hazardous Substances Data: 133031-38-6(Hazardous Substances Data)

Usage

Description

(2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one is a chalcone compound with the molecular formula C15H9Cl3O. It is a yellow solid that is insoluble in water but soluble in organic solvents. Chalcones are natural phenolic compounds found in many plants and have been studied for their potential biological activities, including antioxidant, anti-inflammatory, and anticancer properties.

Uses

Used in Pharmaceutical Industry:
(2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one is used as a pharmaceutical compound for its potential biological activities. Its antioxidant, anti-inflammatory, and anticancer properties make it a promising candidate for further research and development in the pharmaceutical industry.
Used in Chemical Research:
(2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one is used as a research compound in chemical studies. Its unique properties and potential applications in various fields make it an interesting subject for further investigation and experimentation.
Note: The specific properties and uses of (2E)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one may vary depending on further research and testing.

Upstream product

• 99-91-2 para-chloroacetophenone 
• 874-42-0 2,4-dichlorobenzaldeyhde 

Downstream Products

• 170939-29-4 (4-Chloro-phenyl)-[4-(2,4-dichloro-phenyl)-1H-pyrrol-3-yl]-methanone 
• 133031-42-2 (2R,3R,4S,6S)-3-(4-Chloro-benzoyl)-4-(4-chloro-phenyl)-2,6-bis-(2,4-dichloro-phenyl)-4-hydroxy-cyclohexane-1,1-dicarbonitrile 

Relevant articles and documents

Aryl-4,5-dihydro-1H-pyrazole-1-carboxamide derivatives bearing a sulfonamide moiety show single-digit nanomolar-to-subnanomolar inhibition constants against the tumor-associated human carbonic anhydrases IX and XII

A series of new 3-phenyl-5-aryl-N-(4-sulfamoylphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide derivatives was designed here, synthesized, and studied for carbonic anhydrase (CAs, EC 4.2.1.1) inhibitory activity against the human (h) isozymes I, II, and VII (cytosolic, off-target isoforms), and IX and XII (anticancer drug targets). Generally, CA I was not effectively inhibited, whereas effective inhibitors were identified against both CAs II (KIs in the range of 5.2-233 nM) and VII (KIs in the range of 2.3-350 nM). Nonetheless, CAs IX and XII were the most susceptible isoforms to this class of inhibitors. In particular, compounds bearing an unsubstituted phenyl ring at the pyrazoline 3 position showed 1.3-1.5 nM KIs against CA IX. In contrast, a subset of derivatives having a 4-halo-phenyl at the same position of the aromatic scaffold even reached subnanomolar KIs against CA XII (0.62-0.99 nM). Docking studies with CA IX and XII were used to shed light on the derivative binding mode driving the preferential inhibition of the tumor-associated CAs. The identified potent and selective CA IX/XII inhibitors are of interest as leads for the development of new anticancer strategies.

Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease

Methods are provided for treating chronic obstructive pulmonary diseases such as emphysema using compounds that activate the signaling pathways of hepatocyte growth factor.